Foscarnet
Foscarnet, Foscavir (foscarnet) is a small molecule pharmaceutical. Foscarnet was first approved as Foscavir on 1991-09-27. It is used to treat cytomegalovirus infections and herpes genitalis in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| urogenital diseases | D000091642 |
Trade Name
FDA
EMA
Foscarnet, Foscavir (discontinued: Foscarnet)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| foscarnet | ANDA | 2021-06-09 |
| foscarnet sodium | ANDA | 2024-07-19 |
| foscavir | New Drug Application | 2023-11-02 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| cytomegalovirus infections | EFO_0001062 | D003586 | B25 |
| herpes genitalis | EFO_0007282 | D006558 | A60 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J1455 | Injection, foscarnet sodium, per 1000 mg |
Clinical
Clinical Trials
37 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 7 | 4 | 4 | 2 | 6 | 23 |
| Infections | D007239 | EFO_0000544 | — | 5 | 2 | 2 | 2 | 5 | 16 |
| Cytomegalovirus infections | D003586 | EFO_0001062 | B25 | — | 4 | 3 | 3 | 3 | 13 |
| Cytomegalovirus retinitis | D017726 | EFO_1001302 | — | 2 | 4 | 2 | 1 | 4 | 13 |
| Retinitis | D012173 | — | H30.9 | 2 | 4 | 2 | 1 | 4 | 13 |
| Communicable diseases | D003141 | — | — | 3 | — | 2 | 2 | — | 7 |
| Herpes simplex | D006561 | — | B00 | 1 | — | 2 | 1 | 2 | 6 |
| Hypocalcemia | D006996 | HP_0002901 | E83.51 | — | — | — | 1 | — | 1 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | — | — | 1 | — | 1 |
| Viremia | D014766 | — | B34.9 | — | — | — | 1 | — | 1 |
Show 1 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 2 | — | 2 | — | 2 | 6 |
| Cytomegalovirus | D003587 | — | — | — | 1 | 2 | — | 1 | 4 |
| Immunologic deficiency syndromes | D007153 | HP_0002721 | D84.9 | 1 | — | 1 | — | 2 | 4 |
| Papillomavirus infections | D030361 | — | — | — | — | 1 | — | — | 1 |
| Gastrointestinal diseases | D005767 | — | — | — | — | 1 | — | — | 1 |
| Digestive system diseases | D004066 | HP_0011024 | K92.9 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Graft vs host disease | D006086 | — | D89.81 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Brain diseases | D001927 | HP_0001298 | G93.40 | 1 | — | — | — | — | 1 |
| Nervous system diseases | D009422 | — | G00-G99 | 1 | — | — | — | — | 1 |
| Radiculopathy | D011843 | — | M54.1 | 1 | — | — | — | — | 1 |
| Virus diseases | D014777 | — | B34 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mycoses | D009181 | — | B35-B49 | — | — | — | — | 1 | 1 |
| Leukemia | D007938 | — | C95 | — | — | — | — | 1 | 1 |
| Myelodysplastic syndromes | D009190 | — | D46 | — | — | — | — | 1 | 1 |
| Myeloid leukemia acute | D015470 | — | C92.0 | — | — | — | — | 1 | 1 |
| Hematologic neoplasms | D019337 | — | — | — | — | — | — | 1 | 1 |
| Recurrence | D012008 | — | — | — | — | — | — | 1 | 1 |
| Myeloproliferative disorders | D009196 | — | D47.1 | — | — | — | — | 1 | 1 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | — | — | — | — | 1 | 1 |
| Extranodal nk-t-cell lymphoma | D054391 | — | C86.0 | — | — | — | — | 1 | 1 |
| Essential thrombocythemia | D013920 | — | D47.3 | — | — | — | — | 1 | 1 |
Show 56 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Foscarnet |
| INN | foscarnet sodium |
| Description | Phosphonoformic acid is phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity. It has a role as an antiviral drug, a sodium-dependent Pi-transporter inhibitor, a HIV-1 reverse transcriptase inhibitor and a geroprotector. It is a one-carbon compound, a member of phosphonic acids and a carboxylic acid. It is functionally related to a phosphonic acid and a formic acid. It is a conjugate acid of a phosphonatoformate and a phosphonoformate(2-). |
| Classification | Small molecule |
| Drug class | phosphoro-derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C(O)P(=O)(O)O |
Identifiers
| PDB | — |
| CAS-ID | 4428-95-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL666 |
| ChEBI ID | 127780 |
| PubChem CID | 3415 |
| DrugBank | DB00529 |
| UNII ID | 8C5OQ81LWT (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,031 documents
View more details
Safety
Black-box Warning
Black-box warning for: Foscarnet, Foscarnet sodium, Foscavir
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,236 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use